Lead Product(s): mRNA vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: BNT162
Highest Development Status: Phase I/ Phase II Product Type: Vaccine
Recipient: BioNTech SE
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 16, 2020
The potential vaccine is one of the two most advanced candidates that BioNTech is working on with its partner Pfizer Inc and they received “fast track” status this week from the U.S. Food and Drug Administration which is designed to speed up the regulatory review process.
Lead Product(s): Pretomanid
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: TB Alliance
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 16, 2020
The partnership with Hongqi is part of TB Alliance’s global commercialization strategy for pretomanid as part of the BPaL regimen.